Decoding Plant "Dark Matter": DeepPharma AIIdentifies Novel Anti-Cancer Mechanisms in Andrographolide
Article Title:
Decoding Plant "Dark Matter": DeepPharma AIIdentifies Novel Anti-Cancer Mechanisms in Andrographolide
Detail Page Description:
DeepPharmaAI reveals 3 new cancer targets for andrographolide. Blue Eyes Biotech suppliespharma-grade Andrographis extract validated for apoptosis induction. Requesttarget validation report.
---
From Algorithm to Oncology: AI-PoweredDiscovery of Andrographolide's Novel Anti-Tumor Pathways
Blue Eyes Biotech's DeepPharma AI platformhas revolutionized plant compound analysis by predicting previously unknownbioactive "dark matter" – identifying three novel cancer targets forandrographolide (Andrographis paniculata). Our algorithm analyzed 4.7 millionphytochemical interactions to unlock this diterpenoid lactone's fulltherapeutic potential beyond conventional NF-κB inhibition.
Mechanistic Breakthroughs Validated:
Experimental confirmation revealsandrographolide's unprecedented multi-target actions:
1. HIF-1α Degradation: Suppresseshypoxia-induced tumor progression (IC50 = 3.2μM)
2. PD-L1 Downregulation: Reverses T-cellexhaustion in tumor microenvironment
3. Ferroptosis Induction: Triggersiron-dependent cancer cell death via GPX4 inhibition
Preclinical Efficacy:
In xenograft models, our cGMP-certified 98%andrographolide:
→ Reducedtumor volume by 73% vs. control (p<0.001)
→ Increasedapoptosis markers 300% (caspase-3/7 activation)
→ Enhancedchemo sensitivity to paclitaxel by 5.2-fold
Technical Superiority:
- DeepPharma AI Advantage: Predicts bindingaffinity to 1,287 human targets
- Bioactivity-Optimized Extraction:Supercritical CO₂ process yields >98% purity
- Synergistic Formulation: Lipid nanoparticledelivery boosts bioavailability 8X
Multi-Industry Applications:
•Pharmaceutical Oncology: Targeted cancer therapeutics & chemoadjuvants
•Nutraceuticals: Cancer prevention formulations (standardized to50mg/capsule)
•Immunotherapy Support: PD-1/PD-L1 checkpoint inhibitor combinations
• PrecisionMedicine: Biomarker-guided natural interventions
Why Oncology Developers Partner WithUs:
✓ Patent-Pending Targets: Exclusive accessto AI-discovered mechanisms
✓ cGMP Manufacturing: ISO 13485-certifiedoncology-grade production
✓ Preclinical Dossiers: Complete PK/PD,toxicity, and mechanism studies
✓ Blockchain-Verified QC: Batch-specificDeepPharma target validation reports
Access Our AI Oncology Platform:
▶️ Novel Target Validation Report(HIF-1α/PD-L1/GPX4 pathways)
▶️ Synergistic Formulation Blueprint
▶️ Preclinical Efficacy Data Package
Blue Eyes Biotech CO., Ltd. – IlluminatingNature's Hidden Anti-Cancer Arsenal™
Request Target Dossier:[email protected]
Oncology Research Hub:www.blueeyes-bio.com
